Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PDS0101 + chemoradiation therapy
- Development stage
- Unknown
- Lead developer
- PDS Biotech
- Modality
- Implantable Devices → Device-based Delivery → Drug Delivery Systems, Small Molecules, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Intravenous
01
Overview
PDS0101 in combination with chemoradiation therapy is an investigational treatment regimen being developed for locally advanced cervical cancer. PDS0101 is a subcutaneous HPV-specific T cell immunotherapy based on the proprietary Versamune platform, designed to target and induce a potent T cell response against HPV16 E6 and E7 oncoproteins. In this combination approach, PDS0101 is administered alongside standard-of-care chemoradiotherapy (CRT) to enhance the immune system's ability to clear HPV-positive tumor cells. The regimen is currently being evaluated in the Phase 2 IMMUNOCERV trial, specifically for patients with high-risk, locally advanced squamous cell cervical cancer with lymph node metastasis or large tumors. Preliminary data has shown high overall response rates and significant tumor shrinkage with a manageable safety profile.
- Brand names
- Versamune HPV
- Other names
- PDS0101 + CRTPDS0101 + chemoradiotherapy
02
Targets
HPV16 E6 oncoprotein
Beyond the preview
Go deeper on PDS0101 + chemoradiation therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PDS0101 + chemoradiation therapy.